Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOVENT vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
40% bound primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg, approximating total body water.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 96%; sustained-release: 80-90%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
GFR 30-50 m L/min: reduce dose by 25%. GFR 10-29 m L/min: reduce dose by 50%. GFR <10 m L/min: reduce dose by 75% or extend interval to every 24 hours.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75% or consider alternative therapy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Oral: 5-10 mg/kg every 12 hours; maximum 400 mg/day. Intravenous: 5 mg/kg loading dose, then 5 mg/kg every 12 hours.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Initiate at 200 mg every 12 hours; increase cautiously to 400 mg every 12 hours; monitor renal function and adjust per renal guidelines.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
High risk of toxicity with narrow therapeutic index; monitor serum levels,Use caution in patients with cardiac disorders (e.g., arrhythmias), liver disease, renal impairment, seizure disorders, or peptic ulcer disease,Drug interactions with fluoroquinolones, macrolides, cimetidine, allopurinol, and others can increase theophylline levels,Cigarette smoking and certain anticonvulsants can decrease theophylline levels
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component,Seizure disorder not adequately controlled,Active peptic ulcer disease
Hypersensitivity to theophylline or any component of the formulation.
Avoid high-fat meals as they can alter absorption of sustained-release formulations. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) may increase the risk of toxicity and should be limited. Charcoal-grilled foods and a high-protein diet may reduce theophylline clearance, while a high-carbohydrate diet may increase clearance; maintain consistent diet.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnancy category C.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Excreted in breast milk; M/P ratio approximately 0.6; use with caution, monitor infant for irritability and tachycardia.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Increased clearance in late pregnancy may require dose increase; monitor serum levels and adjust to maintain therapeutic range (5-15 mcg/m L).
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
THEOVENT is a brand of theophylline, a methylxanthine bronchodilator. Narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Caffeine and other methylxanthines can increase toxicity. Smoking induces metabolism, requiring dose adjustments. Consider alternative in acute exacerbations due to slow onset.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it can increase side effects.,Do not smoke or stop smoking without medical advice, as smoking affects how the drug works.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Take with food if gastrointestinal upset occurs.,Do not crush or chew extended-release tablets; swallow whole.,Keep a regular dosing schedule to maintain consistent blood levels.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOVENT vs AEROLATE JR, answered by our medical review team.
THEOVENT is a Bronchodilator that works by Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOVENT and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOVENT is: Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOVENT and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOVENT is classified as Category C. First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnan. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.